Stand Up To Cancer and Prostate Cancer Foundation Announce New Dream Team

Posted date

Stand Up To Cancer (SU2C) and the Prostate Cancer Foundation (PCF), along with the American Association for Cancer Research (AACR), SU2C's scientific partner, announced the formation of a new Dream Team dedicated to prostate cancer research at the AACR Annual Meeting 2012, held in Chicago.

Arul M. Chinnaiyan, MD, PhD, of the University of Michigan, and Charles L. Sawyers, MD, of Memorial Sloan-Kettering Cancer Center, will lead the Dream Team project titled "Precision Therapy for Advanced Prostate Cancer." The Dream Team includes Philip Kantoff, MD, and Levi Garraway, MD, PhD, from Dana-Farber Cancer Institute and scientists drawn from leading prostate cancer clinical research centers in the U.S. and England.

The SU2C-PCF Prostate Dream Team Translational Cancer Research Grant will provide funding of $10 million over a three-year period for a seven-center project including both clinical centers and two research infrastructure sites that will address therapeutic interventions for advanced prostate cancer with special emphasis on metastatic disease, and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, synergistic Dream Team of expert investigators.

"Through this unique partnership with PCF, we will focus critically needed research on advanced prostate cancer," said Sherry Lansing, one of SU2C's co-founders. "Our collective goal is to produce personalized treatment approaches that will begin to benefit patients in the next few years."

"We are excited to announce and fund this Dream Team in partnership with Stand Up To Cancer. Healthy competition for the prestigious research award brought out tremendous innovation — well beyond what the National Cancer Institute or Department of Defense is currently funding," commented Jonathan Simons, M.D., president and CEO of the Prostate Cancer Foundation.

"We are highly confident that the cross-institutional teams of researchers led by Drs. Chinnaiyan and Sawyers will significantly fast-forward actionable therapeutic sciences for men with treatment-resistant metastatic prostate cancer."


Media Contacts

If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email media@dfci.harvard.edu.

The Media Team cannot respond to patient inquiries. For more information, please see Contact Us.